COMMUNIQUÉS West-GlobeNewswire

INNATE PHARMA, First half of 2017: delivering key clinical data and strengthening the pipeline

18/09/2017 - 07:00

first half of 2017: DELIVERING KEY CLINICAL Data and strengthening the Pipeline Cash, cash equivalents and financial assets [1] for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant [...]

Addex Makes Changes to Executive Management Team

18/09/2017 - 07:00

Geneva, Switzerland, 18 September 2017 - Addex Therapeutics (SIX: ADXN) announced today that Robert Lutjens, Head of Discovery will join the Executive Management Team and take over scientific leadership with support [...]

Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption

16/09/2017 - 16:00

OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous [...]

Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

16/09/2017 - 08:15

Sanofi and Regeneron Announce Positive Study Results for Dupixent ® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis - Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European [...]

Sanofi et Regeneron annoncent les résultats positifs d'une étude consacrée à Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère

16/09/2017 - 08:15

Sanofi et Regeneron annoncent les résultats positifs d'une étude consacrée à Dupixent ® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère - Présentation orale des résultats de l'étude de phase 3 [...]

Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment Option

15/09/2017 - 19:29

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc (" [...]

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 août 2017

15/09/2017 - 17:00

Communiqué de presse Villepinte, le 15 septembre 2017 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]

Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress

15/09/2017 - 13:00

Shire Debuts MYDAYIS ® and New Research at the 30 th Annual Psych Congress Lexington, MA - September 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) will share new Attention Deficit Hyperactivity Disorder (ADHD) research [...]

Tresiba® trial shows that people with type 2 diabetes who avoid severe hypoglycaemia have a reduced risk of death

15/09/2017 - 09:31

PR170915_EASD_Tresiba_UK This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Solon Eiendom ASA : Primary insider notification

15/09/2017 - 08:30

(Oslo, Norway, 14 September 2017) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien AS) has today bought 25 373 shares in Solon Eiendom ASA at a price of NOK 17,5908. Following [...]

Skåne University Hospital Becomes First Clinic in Sweden To Use Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease

15/09/2017 - 08:00

Press release Malmö, September 15, 2017 Skåne University Hospital Becomes First Clinic in Sweden To Use Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease The company's roll-out program on track as [...]

FIT Biotech Oy: FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2017

15/09/2017 - 08:00

FIT Biotech Oy Company release September 15th, 2017 at 9:00 EET FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2017 (unaudited) This company release is a summary of FIT Biotech's Half Year Financial [...]

Herantis Pharma receives Life Sciences Nordic Stars Award

15/09/2017 - 07:30

Herantis Pharma receives Life Sciences Nordic Stars Award Herantis Pharma Plc Press release 15 Sep 2017 at 8:30 am Herantis Pharma plc ("Herantis") received the Nordic Stars Award at the Nordic Life Sciences Days in [...]

Fagron NV: Disclosure of received notification

15/09/2017 - 07:00

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands) 1 , 15 September 2017 Disclosure of received notification Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in [...]

Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization Application for Raxone® in DMD and Intends to Appeal this Opinion

15/09/2017 - 07:00

Liestal, Switzerland, September 15, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative [...]

Independent Data Monitoring Committee Recommends Discontinuation of Bavarian Nordic's Phase 3 Study of PROSTVAC in Metastatic Prostate Cancer

14/09/2017 - 22:01

Conference call scheduled for 2:00 PM CEST / 8:00 AM EDT tomorrow, Friday, September 15 COPENHAGEN, Denmark, September 14, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that an independent Data [...]

AB Science annonce que le CHMP a adopté une opinion négative pour l'enregistrement du masitinib dans la mastocytose systémique indolente après réévaluation du dossier

14/09/2017 - 18:47

Paris, 14 septembre 2017, 18h30 AB Science annonce que le CHMP a adopté une opinion négative pour l'enregistrement du masitinib dans la mastocytose systémique indolente, après réévaluation du dossier AB Science SA (NYSE [...]

AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment

14/09/2017 - 18:47

Paris, 14 September 2017, 6.30pm AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment AB Science SA (NYSE Euronext - [...]

Guerbet annonce que Vectorio®, un dispositif médical innovant pour les procédures cTACE, a reçu le marquage CE

14/09/2017 - 18:02

Vectorio ® sera présenté lors des prochains congrès de radiologie Villepinte (France), le 14 septembre 2017 (18 heures CEST) - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour [...]